BIOAVAILABILITY AND ADMET

Bioavailability and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling are critical components in modern drug discovery, determining the pharmacokinetic behavior and safety profiles of pharmaceutical candidates. Bioavailability represents the fraction of an administered drug that reaches systemic circulation in active form, directly influencing therapeutic efficacy. Comprehensive ADMET evaluation provides insights into how compounds are absorbed, distributed to tissues, metabolized by enzymatic systems, excreted from the body, and their potential toxicity risks. Predictive rules such as Lipinski's Rule of Five and Veber's Rules have established fundamental criteria for assessing drug-likeness based on molecular weight, lipophilicity, hydrogen bonding capacity, and molecular flexibility. The integration of computational tools including SwissADME, pkCSM, ADMETlab, PreADMET, and Molinspiration has revolutionized early-stage screening by enabling rapid, cost-effective prediction of pharmacokinetic and toxicological properties without extensive laboratory testing. These in silico platforms utilize machine learning algorithms, QSAR modeling, and physicochemical descriptors to predict absorption efficiency, tissue distribution, metabolic stability, clearance pathways, and safety endpoints. Early ADMET assessment significantly reduces late-stage attrition rates, accelerates drug development timelines, and improves the probability of clinical success by identifying compounds with optimal pharmacokinetic profiles and minimal toxicity before costly experimental validation.